Table 4.
Study B, characteristics of the 3 groups during and at end of trial
| Measure | Progressor & Linear (n=352) | Progressor & Nonlinear (n=58) | Non progressor (n=25) | P |
|---|---|---|---|---|
| 50% reduction in eGFR | 155 (44.0%) | 23 (39.7%) | 0 (0%) | < 0.001 |
| Reached any end point * | 184 (52.3%) | 31 (53.4%) | 0 (0%) | < 0.001 |
| Average home SBP during trial (mm Hg) | 118.9 ± 4.9 | 119.9 ± 6.1 | 118.5 ± 8.2 | 0.4 |
| Average home DBP during trial (mm Hg) | 79.1 ± 4.8 | 79.5 ± 5.3 | 78.2 ± 5.9 | 0.6 |
| Average no. of medications needed to control BP (step) | 2.8 ± 2.1 | 3.3 ± 2.5 | 3.1 ± 2.2 | 0.2 |
| Follow-up duration for eGFR (years) | 5.4 ± 1.4 | 4.9 ± 1.6 | 6.6 ± 0.8 | < 0.001 |
| eGFR at study end (ml/min/1.73 m2) or end point | 26.6 ± 10.7 | 28.7 ± 13.3 | 45.4 ± 11.4 | < 0.001 |
| Urine aldosterone at study end (μg/24 h) or end point | 5.2 ± 3.6 | 6.2 ± 5.4 | 5.9 ± 3.6 | 0.1 |
| Time to end point (months) | 67.4 ± 15.9 | 62.1 ± 18.5 | 79.0 ± 10.1 | < 0.001 |
| Weight at study end (kg) | 85.1 ± 19.9 | 85.7 ± 17.9 | 80.9 ± 18.1 | 0.6 |
| Urinary creatinine excretion at study end (mg/24 h) | 1296.4 ± 638.1 | 1372.5 ± 561.8 | 1242.8 ε ± 414.9 | 0.6 |
Note: Values for categorical variables are given as number (percentage); values for continuous variables, as mean ± standard deviation.
*
End points were initiation of dialysis, kidney transplantation, death, or 50% reduction in eGFR.
ε
Excluding the 2 subjects with likely over-collections of urine from the nonprogressor analysis results in ending creatinine excretion of 1280 ± 405 mg/24 h.
BP: blood pressure; DBP, diastolic BP; eGFR: estimated glomerular filtration rate (using Chronic Kidney Disease Epidemiology Collaboration creatinine equation); SBP, systolic BP.